Adlai Nortye Ltd. American Depositary Shares Stock (NASDAQ:ANL)


ForecastRevenueFinancialsChart

Previous Close

$2.28

52W Range

$1.85 - $17.48

50D Avg

$2.32

200D Avg

$5.22

Market Cap

$215.83M

Avg Vol (3M)

$14.76K

Beta

6.28

Div Yield

-

ANL Company Profile


Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

KY

Employees

127

IPO Date

Sep 23, 2023

Website

ANL Performance


ANL Financial Summary


Dec 23Dec 22Dec 21
Revenue$5.00M-$45.73M
Operating Income$-68.38M$-67.27M$-8.65M
Net Income$-104.78M$-58.79M$-56.68M
EBITDA$-66.16M$-57.35M$-54.34M
Basic EPS$-2.42$-0.60$-0.58
Diluted EPS$-2.42$-0.60$-0.58

Fiscal year ends in Dec 23 | Currency in USD